Iberdomide

Iberdomide (CC-220) is Bristol Myers Squibb's next-generation CELMoD (cereblon E3 ligase modulator): a molecular glue designed to do what Revlimid (lenalidomide) does, but harder and against resistant disease. It binds cereblon, the cellular 'tagging' machinery, with >20-fold higher affinity than lenalidomide [8] and forces it to destroy two transcription factors (Ikaros and Aiolos) that multiple myeloma cells need to survive. The lead trial, EXCALIBER-RRMM (NCT04975997), tests iberdomide/daratumumab/dexamethasone (IberDd) against daratumumab/bortezomib/dexamethasone (DVd) in relapsed/refractory patients who have already seen lenalidomide [1]. In September 2025, BMS announced a positive interim analysis: EXCALIBER met one of its dual primary endpoints - minimal residual disease (MRD) negativity, the deepest available measure of myeloma response - with statistical significance [11]. The FDA accepted BMS's New Drug Application in February 2026, granting both Breakthrough Therapy Designation and Priority Review, with a target action date of August 17, 2026 [12]. The progression-free survival (PFS) co-primary readout and overall survival (OS) secondary are still maturing. This is BMS's swing at extending an IMiD franchise that earned ~$12B/year at peak with Revlimid before generic entry [9], and the program has cleared its first regulatory hurdle. Multiple Phase 1 combination studies with the bispecifics teclistamab (J&J) and elranatamab (Pfizer), plus post-CAR-T maintenance trials, hedge against a future where bispecifics replace IMiDs as backbone therapy [2][3].

Iberdomide is investigational, not yet approved anywhere. The NDA (in combination with daratumumab + dexamethasone) was accepted by the FDA in February 2026 with Breakthrough Therapy Designation and Priority Review; PDUFA target action date is August 17, 2026 [12]. The drug originated at Celgene and came to BMS through the 2019 Celgene acquisition. EXCALIBER-RRMM (Phase 3, NCT04975997) is the lead trial; the September 2025 interim readout met the MRD-negativity dual primary endpoint and the trial continues toward PFS and OS maturation [11]. Multiple Phase 1/2 programs run in parallel: NCI's teclistamab + iberdomide combo (NCT06465316) [2], Pfizer's MagnetisMM-30 with elranatamab (NCT06215118) [3], Memorial Sloan Kettering's post-AHCT (autologous hematopoietic cell transplant) trial (NCT05354557) [4], and an NCI post-CAR-T maintenance study (NCT06179888) [5]. The Phase 2 ICON study (iberdomide + cyclophosphamide + dexamethasone) reported in Lancet Haematology 2026 [6]. Outside oncology, iberdomide is being tested in systemic lupus erythematosus, where molecular endotype analysis showed differential response [7]. SLE is a secondary story; the multiple myeloma franchise is what's at stake commercially.

Cereblon (CRBN) is a substrate adapter in an E3 ubiquitin ligase complex. Think of it as the cell's 'label maker' that decides which proteins get tagged with ubiquitin and sent to the proteasome for shredding. Normally cereblon picks specific substrates. The IMiD (immunomodulatory imide) drugs - thalidomide, lenalidomide, pomalidomide - hijack it, redirecting cereblon to grab two transcription factors, Ikaros (IKZF1) and Aiolos (IKZF3), that multiple myeloma cells depend on for survival and growth. Destroy Ikaros/Aiolos, and myeloma cells die. Iberdomide is a CELMoD (Cereblon E3 Ligase Modulator), engineered to do this more potently. It binds CRBN with >20-fold higher affinity than lenalidomide or pomalidomide, induces a more efficient allosteric rearrangement of CRBN, and drives faster and deeper degradation of Ikaros/Aiolos [8]. That extra affinity matters because of how IMiD resistance works. Lenalidomide/pomalidomide resistance is dominated by cereblon changes: reduced CRBN expression, copy losses, exon-10-spliced variants, and point mutations. CRBN alterations are rare (<1%) in newly diagnosed myeloma but rise to ~12% in IMiD-treated and approach one-third of patients by pomalidomide-refractory progression [13]. Iberdomide retains activity in CRBN-low (reduced-expression) and many CRBN-mutant settings where lenalidomide/pomalidomide fail, because higher binding affinity offsets reduced or altered substrate adapter. Iberdomide cannot rescue CRBN-null cells - if cereblon is gone, there is no adapter to glue to - and certain CRBN mutations (e.g., those disrupting the thalidomide-binding domain itself) blunt CELMoD activity broadly. CC-220-MM-001 Phase 1/2 monotherapy + dexamethasone data in heavily pretreated, mostly triple-class-refractory patients showed an objective response rate (ORR; fraction of patients with ≥partial response) of 26.2%, modest as a single agent but meaningful in a population where most options have failed [8]. The mechanism is as validated as cancer biology gets: lenalidomide generated roughly $12B in 2021 sales for BMS before generic entry [9]. The CELMoD bet is that higher-affinity CRBN binding translates to durable activity in IMiD-refractory disease - and the EXCALIBER MRD interim suggests that bet is paying off in the daratumumab combination [11].

EXCALIBER-RRMM (NCT04975997) is the commercially decisive trial. Randomized Phase 3, iberdomide/daratumumab/dexamethasone (IberDd) vs daratumumab/bortezomib/dexamethasone (DVd) in patients with 1-2 prior lines of therapy, lenalidomide-exposed [1]. The trial uses dual primary endpoints - MRD (minimal residual disease - the presence of myeloma cells detectable only by sensitive molecular tests after apparent remission) negativity and PFS. Key secondary endpoints include OS, ORR, duration of response, time to progression, and time to next treatment [1][11]. In September 2025, BMS reported that the planned interim analysis met the MRD-negativity endpoint with statistical significance; the trial continues to read out PFS and OS [11]. The dual-primary MRD/PFS design is important post-Project Optimus and in the broader FDA shift toward earlier, deeper response measures - but PFS-only or PFS-plus-MRD approvals still face scrutiny for whether OS trends are at least non-detrimental at maturity. Historical comparable myeloma Phase 3 trials in this setting typically show OS data that is immature at PFS readout; expect the OS picture to evolve over years post-approval. The design is sound - DVd is a real-world standard of care, not a strawman comparator. The lenalidomide-exposed population is the test case: it's where IMiD-class drugs typically lose efficacy, and where iberdomide must show it's not just Revlimid-redux. EXCALIBER's specific enrollment target has not been publicly disclosed at a level I can cite confidently, so I'm flagging enrollment_target as null. The trial opened in 2021 and recruitment supported an interim by mid-2025. The node references NCT05434689, a small Phase 1 single-center trial testing combination regimens post-autologous hematopoietic cell transplant (AHCT) to drive MRD-negative status [10]. Useful science, not a commercial driver. The wider combination program is strategically important: NCT06465316 (teclistamab + iberdomide) [2] and NCT06215118 (elranatamab + iberdomide, MagnetisMM-30) [3] position iberdomide as a tolerable add-on to bispecifics. NCT06179888 tests iberdomide as maintenance after ide-cel (idecabtagene vicleucel, the BMS BCMA-directed CAR-T) [5]. BMS is hedging against a future where bispecifics and CAR-T therapies replace IMiDs as backbone therapy.

This drug is under FDA review (NDA/BLA), with a PDUFA decision date of 2026-08-17. Our estimate of 88% is the historical filing-approval rate for its area, adjusted for its rejection history (no prior Complete Response Letters). At this stage the early-trial design model no longer applies - what matters is that it reached the FDA and whether it has been rejected before.

Efficacy risk is now concentrated in the PFS and OS readouts, not the MRD readout (which is in hand). MRD-negativity is a strong surrogate but the FDA, payers, and NCCN guideline committees will look hard at whether PFS magnitude justifies adoption over DPd and other established triplets, and whether OS shows at least non-detrimental trends. If PFS hazard ratio comes in shallow (e.g., ~0.85) or OS trends adversely, the franchise-extension thesis weakens even with FDA approval. Safety risk: CELMoD class effects mirror IMiDs - neutropenia, infections, fatigue, thromboembolism [8]. Combining with daratumumab compounds infection risk, and real-world tolerance in older, frail multiple myeloma patients is where post-marketing problems usually surface. There is also CRBN-mutation-driven primary resistance risk: iberdomide overcomes CRBN-low disease but not CRBN-null or certain thalidomide-binding-domain mutations [13], which will produce a fraction of non-responders in the lenalidomide-refractory population. Execution risk is low - BMS has run dozens of Phase 3 multiple myeloma trials. Commercial risk is the loaded question. Iberdomide enters a market crowded with bispecifics (teclistamab, elranatamab, talquetamab) and CAR-T therapies (ide-cel = BMS's idecabtagene vicleucel; cilta-cel = J&J/Legend's ciltacabtagene autoleucel) that are moving earlier in the treatment sequence. Each bispecific approval shrinks the IMiD-eligible window. BMS is hedging by running iberdomide combinations with the bispecifics [2][3], but those drugs belong to J&J and Pfizer. Patent/exclusivity runway is a known unknown that cannot be quoted precisely from public sources - composition-of-matter for the CC-220 chemotype originated in Celgene-era filings, and US data exclusivity provides at minimum 5 years from approval (7 with orphan if granted, 12 if it qualified as a biologic, which it does not because iberdomide is a small molecule). A focused Orange Book / SEC review at approval would be required to call the exclusivity envelope precisely. Revlimid's $12B peak to iberdomide's pomalidomide-comparable run-rate ($3-4B) is the realistic envelope; doubling that requires dominating the lenalidomide-refractory backbone position before bispecifics finish moving up the treatment sequence.

Worth watching, now de-risked at the first hurdle. The interim MRD signal in September 2025 [11] plus the February 2026 NDA acceptance with Breakthrough Therapy Designation and Priority Review [12] move iberdomide from 'binary Phase 3 bet' to 'high-probability approval, with magnitude TBD.' The next catalysts: PDUFA action date August 17, 2026; EXCALIBER PFS topline (likely ASCO/EHA or ASH 2026/2027 window); MagnetisMM-30 [3] and the NCI teclistamab combo [2] earlier readouts on safety and recommended Phase 2 dose (RP2D - the dose level selected for Phase 2 expansion based on Phase 1 tolerability and pharmacokinetics) for bispecific combinations. Commercial signal is the PFS hazard ratio: ~0.70 or better gets iberdomide solid NCCN guideline placement and a $2-3B peak trajectory; ~0.85 gets approval but kills the franchise-extension story. BMS needs this drug at the corporate level. Revlimid revenues fell 41% year-over-year in H1 2025 due to generic erosion, and BMS's Legacy Portfolio (which includes Revlimid, Pomalyst, Sprycel, Abraxane) was down ~20% in 2025 [14]. Pomalyst is mid-life-cycle and mezigdomide (CC-92480) sits behind iberdomide as the next CELMoD bet. The hematology franchise has lost multiple billions in run-rate revenue since 2022, and the BMS investor narrative depends on at least one of the two CELMoDs clearing Phase 3 and the bispecific/CAR-T programs holding share. Iberdomide is now the IMiD franchise's first real shot at renewal that has cleared a meaningful regulatory checkpoint.